NCT02091440已完成不适用
Clinical Evaluation of the HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure
Medtronic Cardiac Rhythm and Heart Failure5 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2014年3月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 5
- 主要终点
- Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days
研究概览
简要总结
The purpose of the study is to evaluate the safety and effectiveness of the HW005 System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death.
详细描述
The primary endpoint is success at 180 days which is expressed as a simple proportion and defined as alive on the originally implanted HW005 or transplanted or explanted for recovery. Patients must survive 60 days post-explant for recovery to be considered successful. The primary endpoint is not statistically powered. The six eligible implanted cases will be evaluated as a proportion of success accompanied by a 95% exact confidence interval and presented alongside the ADVANCE results for visual comparison.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with irreversible end-stage heart failure of New York Heart Association (NYHA) class III or IV and a history of class IV who are eligible for heart transplantation.
- •Patients who are dependent on medication of inotropes or intra-aortic balloon pump (IABP).
- •Body Surface Area (BSA) ≥1.2 m
- •In addition other factors may be taken into consideration, including chest size, abdominal fat (lack of abdominal fat may preclude a pump pocket) and any other physical characteristics that might be benefited by an intra-pericardial pump in a small person.
- •Patients who are aged less than 65 years of age.
- •Patients must be able to understand the limits and complications associated with the HW005 Ventricular Assist System.
- •Female patients of childbearing potential must agree on contraception for the duration of the study.
- •The patient or the legal representative has signed the informed consent form.
排除标准
- •Severe illness other than heart disease which would exclude cardiac transplantation.
- •Inadequate family/social support.
- •Active, uncontrolled infection despite appropriate antibiotic, antiviral or antifungal treatment.
- •Existence of any ongoing mechanical circulatory support (MCS) other than an IABP.
- •Prior cardiac transplant or cardiomyoplasty.
- •Acute myocardial infarction within 14 days of implant.
- •Uncorrected thrombocytopenia or generalized coagulopathy.
- •Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.
- •Patients for whom the use of a left ventricular assist device (LVAD) is contraindicated due to an ongoing aortic/cardiac aneurysm, intraventricular septum rupture and/or use of a mechanical heart valve.
- •Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy.
- •Patients with irreversible hepatic dysfunction.
- •Patients with irreversible renal dysfunction.
- •Patients with serious chronic obstructive pulmonary disease (COPD) (Forced Expiratory Volume in the first second (FEV1) < 50%).
- •Pulmonary vascular resistance is unresponsive (fixed) to pharmacologic manipulation as demonstrated by a pulmonary artery systolic pressure exceeding 60mmHg in conjunction with any one of the two following variables:
- •Pulmonary vascular resistance is greater than 6 Woods Units or
- •Transpulmonary gradient exceeds 15 mmHg
- •Cardiothoracic surgery within 14 days of implantation.
- •Peripheral vascular disease with rest pain or ischemic ulcers of the extremities.
- •Pulmonary embolus within three weeks of enrollment as documented by computed tomography (CT) scan or nuclear scan.
- •Patients have moderate to severe aortic insufficiency without plans for correction during pump implantation surgery. Correction may include aortic valve repair at the time of implant.
- •The patient who has advanced calcification in the ascending aorta and/or the descending aorta.
- •Serious right heart failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) at the time of screening.
- •Patients with severe central nervous system disorder or severe cerebral vascular disorder.
- •Patients with a history of drug intoxication, alcohol dependence.
- •Patients unwilling or unable to comply with study requirements.
- •Patients who refuse transfusion.
- •Patients who in the investigator judgement are deemed to be unsuitable as a subject.
- •Patients who are participating in another clinical trial involving investigational drugs or devices.
研究组 & 干预措施
HW005 Ventricular Assist System
Other
Implant of the HW005 Ventricular Assist System.
干预措施: Implant of the HW005 Ventricular Assist System. (Device)
结局指标
主要结局
Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days
时间窗: 180 days
The primary endpoint is success at 180 days which is defined as alive on the originally implanted HW005 Ventricular Assist System or transplanted or explanted for recovery. Patients must survive 60 days post-explant for recovery to be considered successful.
次要结局
- Number of Participants Alive on the Implanted HW005 Ventricular Assist System at 180 Days(180 days)
- Incidence of All Device Failures and Device Malfunctions.(Through study completion, an average of 44.5 months)
- Change in Patient 6-minute Walk Distance (Patient Functional Status) at 6 and 24 Months(Screening, Month 6 (180 days) and Month 24 (after FU completion))
- Incidence of All Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs)(Through study completion, an average of 44.5 months)
- Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life Score at 6 and 24 Months(Screening, Month 6 (180 days) and Month 24 (after follow-up (FU) completion))
- Change in NYHA Patient Classification (Patient Functional Status) at 6 and 24 Months(Screening, Month 6 (180 days) and Month 24 (after FU completion))
研究者
研究点 (5)
Loading locations...
相似试验
已完成
不适用
The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE TrialChronic Heart FailureNCT01166347Medtronic Cardiac Rhythm and Heart Failure451
撤回
不适用
CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass for Pediatric PatientsHeart FailureNCT01171950Abbott Medical Devices
Unknown
不适用
Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW NeonatesRespiratory Distress Syndrome In Premature InfantsNCT02445040Draeger Medical Systems, Inc.225
招募中
不适用
Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic ShockCardiogenic ShockNCT06646224Shenzhen Core Medical Technology CO.,LTD.50
已完成
不适用
Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart FailureChronic Heart FailureNCT00751972Medtronic Cardiac Rhythm and Heart Failure140